NYSE · ELAN
Healthcare · Drug Manufacturers - Specialty & Generic
$22.92
Up+$0.38 (+1.69%)
Updated Oct 10, 2026, 5:20 PM
SID Score
5.0/10
Composite research score
Smart Money
54/100
Neutral
Price performance · ELAN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ELAN closed at $22.92 after 21 trading sessions, down 1.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $22.59 | $22.975 | $22.42 | $22.92 | 2.52M |
| Oct 8, 2026 | $22.08 | $22.625 | $22.00 | $22.54 | 4.57M |
| Oct 7, 2026 | $22.26 | $22.62 | $22.16 | $22.36 | 4.2M |
| Oct 6, 2026 | $22.72 | $23.04 | $22.23 | $22.48 | 7.04M |
| Oct 5, 2026 | $22.09 | $22.725 | $21.72 | $22.51 | 4.79M |
| Oct 2, 2026 | $22.04 | $22.36 | $21.77 | $22.14 | 5M |
| Oct 1, 2026 | $22.32 | $22.50 | $21.62 | $21.77 | 5.87M |
| Sep 30, 2026 | $22.60 | $22.86 | $22.35 | $22.39 | 5.36M |
| Sep 29, 2026 | $22.48 | $22.685 | $22.16 | $22.61 | 5.41M |
| Sep 28, 2026 | $22.01 | $22.635 | $21.92 | $22.45 | 6.59M |
| Sep 25, 2026 | $22.35 | $22.715 | $22.10 | $22.31 | 6.45M |
| Sep 24, 2026 | $22.59 | $22.626 | $21.75 | $22.35 | 7.64M |
| Sep 23, 2026 | $22.82 | $23.385 | $22.51 | $22.57 | 5.34M |
| Sep 22, 2026 | $22.53 | $23.18 | $22.51 | $22.93 | 5.61M |
| Sep 21, 2026 | $22.58 | $22.58 | $22.165 | $22.43 | 4.61M |
| Sep 18, 2026 | $22.77 | $22.88 | $22.275 | $22.42 | 7.95M |
| Sep 17, 2026 | $23.34 | $23.63 | $22.725 | $22.74 | 4.61M |
| Sep 16, 2026 | $23.08 | $23.40 | $22.685 | $22.86 | 7.03M |
| Sep 15, 2026 | $23.16 | $23.47 | $22.65 | $23.00 | 8.25M |
| Sep 14, 2026 | $23.50 | $23.52 | $23.02 | $23.15 | 3.88M |
| Sep 11, 2026 | $23.20 | $23.32 | $22.65 | $23.17 | 4.74M |
The latest Smart Investors Daily articles mentioning ELAN.
Company
Market Activity
Research & News
ELAN research
Company profile and research snapshot.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Keybanc | Overweight | — |
| Aug 6, 2026 | UBS | Buy | — |
| Jul 22, 2026 | Morgan Stanley | Equal-Weight | — |
| Jun 18, 2026 | TD Cowen | Buy | — |
| May 7, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 26, 2026
Elanco Animal Health (NYSE:ELAN) President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. Simmons said Elanco delivered 10% report
SeekingAlpha · Sep 22, 2026
Elanco Animal Health Incorporated (ELAN) Bank of America Global Healthcare Conference 2026 September 22, 2026 9:10 AM EDTCompany ParticipantsJeffrey Simmons...
Yahoo · Sep 17, 2026
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026. Jeff Simmons, president and CEO, will participate in a fireside chat on Tuesday, September 22 at 2:10 p.m. BST (9:10 a.m. EDT).
Yahoo · Sep 15, 2026
Elanco currently trades at $23.15 per share and has shown little upside over the past six months, posting a small loss of 1.1%. The stock also fell short of the S&P 500’s 14.2% gain during that period.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ELAN.
